Our speakers
Diwakar Dayal, Managing Director, SentinelOne
Dominic Goh, Principal, Harbourvest Partners
Dominic Goh joined HarbourVest in 2012 and focuses on secondary investments. This includes analyzing, structuring, and monitoring a wide range of secondary transaction types.
Dominic was previously at Coller Capital where he evaluated secondary opportunities, and contributed to deal sourcing and fundraising efforts in Asia. Prior to that, he was an investment banking associate at ABN AMRO London in the Financial Institutions Group.
Dominic received a BSc (first class honours) in Accounting & Finance from the London School of Economics and Political Science in 2005. Dominic is fluent in Mandarin.
Donald Chan, Managing Director, Asia Pacific, CDP
Dr A.Velumani, Founder, Thyrocare Technologies Ltd
Dr A Velumani, an Ex BARC research scientist is the promotor of Thyrocare Technologies Limited. It was started in 1996, after completing his PhD in Thyroid Pathophysiology and Immunodiagnostics. Today Thyrocare is the industry leader, trend setter and innovators in Indian Diagnostic industry. A company with a network of more than 10,000 Service Centers across the country, its laboratory is certified ISO 9001-2000, accredited by NABL and to keep it ready to take on the global market, in 2007, it has been accredited by the College of American Pathologists (CAP), a global accrediting organisation.
Thyrocare network is vast enough to process in a day 50,000 investigations as on date and it has a capacity to process 5,00,000 investigations per day in its current facilities in Mumbai. This unique, single laboratory model could take on the entire country market, using its innovative and intelligent logistics. Using an air cargo driven logistics for incoming specimens, the laboratory receives every night, same night, before midnight, from 90% of Indian geography. With a backend prowess in IT, this webserver controlled operations deliver reports every morning in every part of the country.
With an impressive volume driven profitablity and focussed, dynamic and scalable model, now it looks at global market and it beleives that it can operate as a global hub for the clinical chemistry segment. Invitro success can be also tried in in-vivo business if ideal partners are identified. It has a compounded annualgrowth of 25% and is doing currently 50 crores of turnover.
Dr Amit Kakar, Managing Partner and Head of Asia, Novo Holdings Equity Asia Pte Ltd
Dr Amit Varma, MD, Healthcare Religare Enterprises Limited
Dr Amit Varma currently operates as President Health Care, Religare Enterprises and Director, Critical Care Medicine, Fortis Escorts group of Hospitals, India. Having completed his MBBS and MD from University of Delhi, Dr Varma further completed his residency from the State University of New York. Thereafter he went on to pursue fellowships in critical care at the University of Pittsburgh Medical Center, and sub specialized in cardiac critical care at the Cleveland Clinic. Alongside this, he also attended courses for an Executive MBA at the University of Chicago.
After almost a decade in USA, Dr Varma began his professional journey in India at the Manipal Heart Foundation in Bangalore. He subsequently moved on to the Narayan Hrudayalaya Hospital as the consultant- in-charge of Critical Care. Early in 2003, Dr Varma joined Fortis Healthcare, where he has and continues to perform multiple administrative and clinical roles. He currently runs the integrated critical care services for Fortis Healthcare ICU network, which today comprises of a strong three-Hundred beds and helps in ormulation of Medical Strategy.
At Religare from 2009, Dr Varma is actively engaged in all healthcare initiatives of the company, playing an advisory and steering role, overlooking and further initiating all healthcare related businesses, providing medical expertise, insight and credibility in all healthcare related verticals such as Health Insurance venture, Healthcare IT, Super Religare Labs and Religare Wellness. He also sits on the Board and Investment committee of the 125$ million Milestone Religare Private Equity fund which is investing domestically in the healthcare and education fields.
Dr Asad Moopen, Chairman, DM Healthcare Pvt. Ltd.
Dr Moopen commenced his journey in healthcare 22 years back in the Middle East. He started his first clinic in Dubai in 1987 with only two doctors and now owns a chain of 70 clinics and pharmacies across GCC countries, the 60-bed Medcare Hospital, Dubai and the 20-bed Al Rafa Hospital for Maternity and Surgery, Dubai.
His strong determination and vision to become the number one in the Asian subcontinent and the Middle East, led him and his team to this great journey towards quality healthcare for all.
Realizing India and the Middle East had recently emerged as favourite destinations for healthcare investment. Dr Azad realized the potential, responded to these emerging markets, & rolled out a five-year roadmap for investing Rs.1,500 Crore in India and the Gulf Cooperative Council (GCC) countries. The MedCity in Kerala, an array of Greenfield projects, acquisitions across India and constructing 10 hospitals and 50 clinics and pharmacies in the GCC countries.Dr Azad Moopen, a true visionary, believes and states that in the race of excellence there is no finishing line.
Dr Ashwin Naik, Co-Founder and CEO, Vaatsalya Healthcare
Ashwin, founder of Vaatsalya, has more than 10 years experience in the life sciences and healthcare industry. Prior to founding Vaatsalya, Ashwin was Vice President of Business Development and Informatics, Triesta Sciences, a specialty clinical research organization involved in conducting advanced genomics based research in the field of oncology. Prior to that, he has worked in various capacities at Molecular Connections (Bangalore/Rockville), Celera Genomics (Maryland), Los Alamos National Laboratory (New Mexico) and Genetic Information Research Institute (California).
Ashwin has a medical degree from Karnatak Medical College, Hubli and a masters degree from University of Houston, Texas.
Dr G.S.K.Velu, MD, Trivitron Medical Services Pvt. Ltd
Dr. G.S.K Velu who has over 18 years of experience in the diagnostics and healthcare industry, and has worked in several multinational companies such as Ciba Corn Diagnostics, Chevron Diagnostics etc., in the capacity of Director (South Asia). He completed his graduation in Pharmaceutical Engineering from BITS Pilani and Post Graduated in Business Administration from Loyala Institute of Administration (LIBA) Chennai and Ph.D in Pharmacology from Indian Board of Alternative Medicines, Calcutta. He is also in the honorary faculty of Sri Ramachandra Hospital and Research Institute (Deemed) University.
He is also in the Board of Several Diagnostics and Medical Devices Companies in India and elsewhere. He is the Founder and Managing Director of one of the most successful medical device and diagnostics company, Trivitron. He contributes with his expertise in corporate marketing and diagnostic sales. He has been awarded the Entrepreneur of the year 2006 by Modern Medicare Magazine which is a leading healthcare magazine.
Dr Geetha Manjunath, Founder, CEO & CTO, NIRAMAI Health Analytix
Dr Geetha Manjunath is the Founder, CEO and CTO of NIRAMAI Health Analytix, and has led the company to develop a breakthrough AI solution for detecting early stage breast cancer in a non-invasive radiation-free manner. Geetha is a Gold Medalist and PhD holder from Indian Institute of Science with management education from Kellogg Chicago. She comes with over 30 years of experience in IT innovation. Before starting NIRAMAI, Geetha was a Lab Director heading AI Research at Xerox and a Principle Scientist at Hewlett Packard Labs.
Geetha has received many international and national recognition for her innovations and entrepreneurial work, including CSI Gold Medal, BIRAC WinER Award 2018 and is on the Forbes List of Top 20 Self-Made Women 2020. She was the winner of Women Health Innovation Showcase Asia in Singapore, Accenture Vahini Innovator of the Year Award from Economic Times and Women Entrepreneur of the Year 2020 by BioSpectrum India. Geetha is an inventor of 50+ US patents, a senior member of the IEEE and a Fellow of the Indian National Academy of Engineering (INAE).
NIRAMAI (which stands for Non-Invasive Risk Assessment with Machine Intelligence) aims to save lives through accessible and early breast cancer detection. One in 12 women are at the risk of breast abnormality, according to World Health Organization. While regular systematised screening programmes have shown to reduce mortality to under 10%, India still sees almost 50% deaths due to breast cancer. Early detection is key to survival, lower treatment cost and higher treatment effectiveness. And, technology has a major role to play here.
It was to bridge this gap, Dr Geetha Manjunath founded Niramai - Non-Invasive Risk Assessment with Machine Intelligence. "As the name suggests, the core technology of our solution is an artificial intelligence led diagnostic platform that uses patented thermal image processing and machine learning algorithms for reliable and accurate breast cancer screening," says Dr. Manjunath.
Niramai's AI-led cancer detection test is called Thermalytix. It is radiation-free, portable, automated, affordable that can be conducted at hospitals or rural areas. "Our aim is to provide affordable high-quality breast healthcare for all," says Dr Manjunath adding how there is no test for screening women under 45 years of age when in India, almost 50% of the ladies detected with breast cancer are under 45. Privacy of patients is of utmost importance at Niramai and unlike mammography, Niramai's imaging method is non-touch, not painful.
Backed by 39 patents and 55+ clinically reviewed publications, The technology has received regulatory clearances, including the US FDA and European CE mark, and has screened over 300,000 women across more than 22 countries. The company partners with hospitals, diagnostic center’s and NGOs to provide screening services.
Calling herself an accidental entrepreneur, Manjunath reminisces how she never planned to start a start-up. However, being on the path for four years now, she considers this the "most fulfilling project" of her life. With a vision to create a cancer-free world and mission to propagate a universal solution to detect early-stage cancer and save lives, Manjunath feels, "we should come together to spread awareness about the need for regular breast cancer screening, its symptoms and risk factors.